Achieving the Composite Endpoint of HbA1c

CONCLUSIONS: Dulaglutide is an effective treatment option, resulting in a similar or greater proportion of patients who reached the HbA1c target of <7.0% (53 mmol/mol), without weight gain or hypoglycaemia compared to active comparators. PMID: 26362460 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26362460?dopt=Abstract

Source: Diabetes Metab - September 12, 2015 Category: Endocrinology Authors: Dungan KM, Raz I, Skrivanek Z, Sealls W, Fahrbach JL Tags: Diabetes Obes Metab Source Type: research